Navigation Links
Xanodyne Pharmaceuticals Appoints New Chief Operating Officer
Date:5/17/2011

NEWPORT, Ky. and MOUNT ARLINGTON, N.J., May 17, 2011 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., is pleased to announce that Fabrice Egros has been appointed to the position of Chief Operating Officer reporting to Natasha Giordano, President and Chief Executive Officer.

Fabrice Egros has more than 20 years of experience in the pharmaceutical industry and prior to Xanodyne served in various senior positions in UCB Pharmaceuticals (Belgium, US and Japan).  His depth of experience includes senior leadership positions in general management, corporate business development, clinical development & regulatory as well as marketing and sales in Europe, Asia and the US at major pharmaceutical companies including Sanofi-Aventis and Parke-Davis.

Mr. Egros said, "I look forward to working with Natasha and the management team in continuing to drive toward our vision of being a leader in the pain management category.  Xanodyne has a proven track record of bringing innovative products to the market and developing strategic partnerships where desired, as well as the people, resources and strategy to focus Xanodyne on high growth opportunities within the pain franchise."  

Ms. Giordano said, "I am very pleased to welcome Fabrice to our management team.  His global knowledge of the industry, deep experience in corporate development and his strong leadership will help us achieve our strategic goals and commercial success in pain management."

About Xanodyne Pharmaceuticals, Inc.

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management. Xanodyne markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins.  Additionally, we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus area.  For more information, visit www.Xanodyne.com.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market
2. Xanodyne Announces Planned President & CEO Succession
3. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
4. Xanodyne Announces Renewed Focus on Pain Management Market
5. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
6. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
7. Access Pharmaceuticals Provides Update on MuGard Commercial Activities
8. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
9. Amylin Pharmaceuticals Files Suit Against Eli Lilly
10. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
11. Reportlinker Adds Pharmaceuticals Reports Bundle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):